PepGen (PEPG)
(Delayed Data from NSDQ)
$16.33 USD
-0.02 (-0.12%)
Updated May 31, 2024 04:00 PM ET
After-Market: $16.36 +0.03 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PEPG 16.33 -0.02(-0.12%)
Will PEPG be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for PEPG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PEPG
Best Momentum Stocks to Buy for April 25th
New Strong Buy Stocks for April 25th
PEPG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?
PepGen (PEPG) Down on Clinical Hold for DM1 Candidate
Other News for PEPG
Bank of America Securities Sticks to Its Buy Rating for PepGen Inc. (PEPG)
PTC Therapeutics rallies 18% on EU authorization update for Translarna
The Prognosis For PepGen
PepGen Inc.: A Buy Rating Ahead of Pivotal Clinical Data Release and Strong Fiscal Health
PepGen reports Q1 results